『ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research』のカバーアート

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

著者： American College of Cardiology
無料で聴く

このコンテンツについて

 The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.American College of Cardiology Foundation. All rights reserved. 衛生・健康的な生活 身体的病い・疾患
エピソード
  • What's the Best Time to Revascularize the Non-culprit Lesions in MVD

    What's the Best Time to Revascularize the Non-culprit Lesions in MVD
    2025/07/15
    Rapid emergency medical services transport to a percutaneous coronary intervention (PCI)-capable hospital is critical for timely intervention and management of life-threatening arrhythmias in ST-elevation myocardial infarction patients. Upon emergency room arrival, immediate transfer to the cath lab is essential to restore perfusion and improve both short- and long-term cardiovascular outcomes, as recommended by clinical guidelines. Interventional cardiologists must also be adept at managing culprit lesions in multivessel disease (MVD) and addressing complications like the no-reflow phenomenon during PCI. In this interview, Drs. Dipti Itchhaporia and Nabil Farag discuss “What's the Best Time to Revascularize the Non-culprit Lesions in MVD.” Suggested Materials: Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145. doi: 10.1093/eurheartj/ehad870.]. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 Mehta SR, Wood DA, Meeks B, et al. Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. Am Heart J. 2019;215:157-166. doi:10.1016/j.ahj.2019.06.006 Subscribe on Apple Podcasts | Subscribe to ACCEL
    続きを読む 一部表示
    9 分
  • Putting it All Together: Cardiogenic Shock Management in 2025 

    Putting it All Together: Cardiogenic Shock Management in 2025 
    2025/07/08
    Cardiogenic shock remains a critical, time-sensitive emergency with a high mortality rate. However, recent advances—particularly multidisciplinary, team-based strategies—have shown promise in improving patient outcomes. With the release of the 2025 ACC Concise Clinical Guidance on Cardiogenic Shock, clinicians now have access to a streamlined, evidence-informed roadmap for early recognition, rapid stabilization, and escalation of care. In this episode, Drs. Glenn A. Hirsch and Shashank S. Sinha explore the latest strategies in cardiogenic shock management in 2025, emphasizing the how the new guidance integrates clinical decision-making tools and highlighting the role of shock teams and regional partnerships in optimizing care delivery. SUGGESTED MATERIALS:   Sinha SS, Geller BJ, Katz JN, et al; American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Kidney in Cardiovascular Disease. Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association. Circulation. 2025 Feb 13. doi: 10.1161/CIR.0000000000001300. Epub ahead of print. PMID: 39945062.  Hall EJ, Agarwal S, Cullum CM, Sinha SS, Ely EW, Farr MA. Survivorship After Cardiogenic Shock. Circulation. 2025 Jan 21;151(3):257-271. doi: 10.1161/CIRCULATIONAHA.124.068203. Epub 2025 Jan 21. PMID: 39836757.  Ton VK, Li S, John K, et al. Serial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report. J Am Coll Cardiol. 2024 Aug 1:S0735-1097(24)07740-4. doi: 10.1016/j.jacc.2024.04.069. Epub ahead of print. PMID: 39217545.    Subscribe on Apple Podcasts | Subscribe to ACCEL 
    続きを読む 一部表示
    12 分
  • Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEF

    Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEF
    2025/07/01

    Heart failure arises when the heart is unable to pump or fill with blood effectively. In the cardiac catheterization lab, we have the unique ability to directly measure the physiological abnormalities underlying this condition, making it the gold standard for diagnosing heart failure. While not every patient requires heart catheterization, it is often essential for those with heart failure with preserved ejection fraction (HFpEF). This is because noninvasive tests, which are commonly used, frequently fall short—providing false reassurance and leading to missed diagnoses. As a result, HFpEF remains underrecognized. And ultimately, a condition that goes unrecognized cannot be properly treated.

    In this interview, Drs. Matthew Martinez and Barry Borlaug discuss “Hemodynamic Assessment for Diagnosis and Treatment Selection in HFpEF.”

    Subscribe on Apple Podcasts | Subscribe to ACCEL

    続きを読む 一部表示
    11 分

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Researchに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。